BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2019 7:45:48 AM | Browse: 912 | Download: 1774
 |
Received |
|
2019-05-20 06:29 |
|
Peer-Review Started |
|
2019-05-23 09:47 |
|
First Decision by Editorial Office Director |
|
2019-07-31 03:49 |
|
Return for Revision |
|
2019-08-20 00:39 |
|
Revised |
|
2019-09-03 13:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-09-12 10:23 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-09-13 04:54 |
|
Articles in Press |
|
2019-09-13 04:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-10-24 12:09 |
|
Publish the Manuscript Online |
|
2019-11-15 07:45 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee and Tae Ho Hong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Myung Ah Lee, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, 222 Banpo-daero, Secho-gu, Seoul 16509, South Korea. angelamd@catholic.ac.kr |
| Key Words |
Pancreatic cancer; Gemcitabine-refractory; Capecitabine; S-1; Second-line treatment; |
| Core Tip |
To date, there is no standard regimen for patients with gemcitabine-refractory pancreatic cancer with poor performance status. In this study, we compared the efficacy and toxicity of capecitabine and S-1 for such patients. The median progression free survival was longer in the S-1 group than in the capecitabine group; however, there were no statistical differences in their overall survival. Among grade 3 or 4 toxicity, hand-foot syndrome was significantly more common in the capecitabine group than in the S-1 group. Thus, oral chemotherapy can be considered as a second-line treatment in gemcitabine-refractory pancreatic cancer patients with poor performance status. |
| Publish Date |
2019-11-15 07:45 |
| Citation |
Park SJ, Kim HH, Shin KS, Hong TH, Lee MA. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 |
| URL |
https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v11.i11.1021 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
